Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM +0.25%88 Equity-to-Asset is 0.21 as of Jun. 2026, which is 13% below its 10-year median of 0.24. GuruFocus rates LTS:0JDM with a GF Score™ of 88/100 and a GF Value™ of $246.27 (Fairly Valued). The stock has 8 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, IQVIA Holdings ranks worse than 86.26% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IQVIA Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $6,171 Mil. IQVIA Holdings's Total Assets for the quarter that ended in Jun. 2026 was $29,881 Mil.
Therefore, IQVIA Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.21.
The historical rank and industry rank for IQVIA Holdings's Equity-to-Asset or its related term are showing as below:
LTS:0JDM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08 Med: 0.24 Max: 0.41
Current: 0.21
During the past 13 years, the highest Equity to Asset Ratio of IQVIA Holdings was 0.41. The lowest was -0.08. And the median was 0.24.
LTS:0JDM's Equity-to-Asset is ranked worse than 86.26% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.6
vs LTS:0JDM: 0.21
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IQVIA Holdings Equity-to-Asset Related Terms
IQVIA Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDM vs WAT, NTRA, A: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IQVIA Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a Equity-to-Asset of 0.21 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IQVIA Holdings and its competitors. This is 13% below median its historical median of 0.24. According to the industry distribution chart, IQVIA Holdings ranks #182 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 86.3%.
Is IQVIA Holdings' Equity-to-Asset too high?
IQVIA Holdings' current Equity-to-Asset of 0.21 is 13% below median its 10-year median of 0.24. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. IQVIA Holdings' value of 0.21 is 65% below this industry median. Based on the distribution chart, IQVIA Holdings ranks #182 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Equity-to-Asset compare to WAT and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #182 out of 211 companies for Equity-to-Asset. This places IQVIA Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.60. IQVIA Holdings' value of 0.21 is 65% below this benchmark. While the company's 10-year median is 0.24 vs. the industry median of 0.60, IQVIA Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Equity-to-Asset of 0.21 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Equity-to-Asset is 0.21, which is 13% below median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Fairly Valued. The stock's GF Value™ is $246.27, compared to a current price of $259.02 — trading 5.2% above its estimated fair value. The current Equity-to-Asset is 0.21, which is 13% below median its 10-year median of 0.24 and 65% below the Medical Diagnostics & Research industry median of 0.60. IQVIA Holdings' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Equity-to-Asset is 0.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be overvalued.
The current stock price of $259.02 is trading 5.2% above its estimated GF Value™ of $246.27.
GuruFocus considers IQVIA Holdings to be Fairly Valued.
Key valuation signals for LTS:0JDM:
Equity-to-Asset: 0.21 (13% below median its 10-year median of 0.24)
GF Value™: $246.27 vs. price of $259.02 (5.2% above fair value)
Industry Position: 65% below the Medical Diagnostics & Research median (#182 of 211)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score
Get the complete analysis for LTS:0JDM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
